High-risk prescribing and incidence of frailty among older community-dwelling men

D. Gnjidic, S. N. Hilmer, F. M. Blyth, V. Naganathan, R. G. Cumming, D. J. Handelsman, A. J. McLachlan, D. R. Abernethy, E. Banks, D. G. Le Couteur

Research output: Contribution to journalArticlepeer-review

183 Scopus citations


Evidence about the association between treatment with high-risk medicines and frailty in older individuals is limited. We investigated the relationship between high-risk prescribing and frailty at baseline, as well as 2-year incident frailty, in 1,662 men 70 years of age. High-risk prescribing was defined as polypharmacy (5 medicines), hyperpolypharmacy (10 medicines), and by the Drug Burden Index (DBI), a dose-normalized measure of anticholinergic and sedative medicines. At baseline, frail participants had adjusted odds ratios (ORs) of 2.55 (95% confidence interval, CI: 1.69-3.84) for polypharmacy, 5.80 (95% CI: 2.90-11.61) for hyperpolypharmacy, and 2.33 (95% CI: 1.58-3.45) for DBI exposure, as compared with robust participants. Of the 1,242 men who were robust at baseline, 6.2% developed frailty over two years. Adjusted ORs of incident frailty were 2.45 (95% CI: 1.42-4.23) for polypharmacy, 2.50 (95% CI: 0.76-8.26) for hyperpolypharmacy, and 2.14 (95% CI: 1.25-3.64) for DBI exposure. High-risk prescribing may contribute to frailty in community-dwelling older men.

Original languageEnglish (US)
Pages (from-to)521-528
Number of pages8
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - Mar 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'High-risk prescribing and incidence of frailty among older community-dwelling men'. Together they form a unique fingerprint.

Cite this